Skip to main content

ADAP

Stock
Health Care
Biotechnology

Performance overview

ADAP Price
Price Chart

Forward-looking statistics

Beta
1.43
Risk
75.74%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.

Company info

SectorHealth Care
IndustryBiotechnology
Employees463
Market cap$260.7M

Fundamentals

Enterprise value$370.3M
Revenue$179.6M
Revenue per employee—
Profit margin-38.91%
Debt to equity-1.30

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)-$0.30
Dividend per share—
Revenue per share$0.70
Avg trading volume (30 day)$165K
Avg trading volume (10 day)$177K
Put-call ratio—

Macro factor sensitivity

Growth+13.5
Credit+32.6
Liquidity-24.4
Inflation+2.5
Commodities+3.0
Interest Rates-0.6

Valuation

Dividend yield0.00%
PEG Ratio-0.66
Price to sales0.37
P/E Ratio-0.66
Enterprise Value to Revenue2.06
Price to book-1.72

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day—
Ex. dividend day—

News

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

We are initiating coverage of Adaptimmune Therapeutics plc ADAP with a 12-month price target of $3.00, translating into sizeable upside from the stock's current price. Adaptimmune designs, develops, manufactures, and delivers innovative cell therapies via the company's unique T-cell receptor (TCR) platform to treat cancers across multiple solid tumor types.

Benzinga (June 17, 2024)
Adaptimmune (ADAP) Down on End of Collaboration With Roche

Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.

Zacks Investment Research (April 15, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free